Aclaris Therapeutics

Aclaris Therapeutics

A company developing treatments for dermatology and immunology.

All edits by  Lena Kourkouta 

Edits on 11 January, 2019
Lena Kourkouta
Lena Kourkouta approved a suggestion from Golden's AI on 11 January, 2019 3:45 pm
Edits made to:
Article (+15/-15 characters)


ATI-502 is a topical JAK1/JAK3 inhibitor that is being investigated (Phase 2) for alopecia areataalopecia areata, including patchy alopecia areata and the more severe forms of the disease, alopecia totalis and alopecia universalis. The product is also under investigation (Phase 2) for androgenetic alopecia, vitiligo, and atopic dermatitis. In July 2017, Aclaris filed an IND (investigational new drug) application for ATI-502.

No more activity to show.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.